May 2021

The Tina Trial: A Phase III randomised placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine “Ice” dependence

Crystalline methamphetamine (“ice”) is a growing concern in Australia. There are no approved medications that can be used to treat dependence on this drug.

Read more
July 2021

National Alcohol and other Drug Workforce Development Strategy

The Australian Government Department of Health has commissioned NCETA to undertake a revision of the National AOD Workforce Development Strategy 20

July 2021

ADF Outcomes Project Blurb

July 2021

UnLEASH Study

Understanding Lesbian, Bisexual and Queer Women’s Experiences of Alcohol, Substance use and Health: The UnLEASH online cohort study

July 2021

Quit Smoking Study

The ‘Quit Smoking Study’ will test how well e-cigarettes can help people quit smoking, when compared with nicotine lozenges or gum.

July 2021

The TINA Trial

NDARC has received a $4.9 m grant to trial a promising new treatment for methamphetamine (also known as ice or crystal meth) use

July 2021

Alcohol policy and intervention effects in Western Australia: A joint initiative in demand-driven research

This project will investigate the impacts of prevention focused alcohol interventions including alcohol policy and regulation on alcohol use, relat

May 2021

Risk communication for people who use illicit drugs: establishing guidance on preferences and behavioural responses to drug alerts

This study seeks to understand the awareness, preferences and responses to communication of drug alerts of people who use illicit drugs.

May 2021

National Alcohol and Other Drug Workforce Development Strategy: Update

Australia’s alcohol and other drug (AOD) workforce is the bedrock of AOD service provision. 

May 2021

Reducing harm from nitrous oxide use

NDRI’s Dr Jodie Grigg was invited to be part of a grant application for National Centre for Clinical Research on Emerging Drugs (NCCRED) Seed Fundi

March 2021

PREFER

The PREFER study aims to evaluate patient preferences for opioid agonist treatment (OAT) in Australia among people who regularly use opioids.

Pages